Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study

NCT04339218 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT04339218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04339218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study
Lead sponsor
Institut Bergonié
Phase
Phase 3
Overall status
Recruiting
Start date
August 28, 2020
Completion date
August 27, 2028
Enrollment
214 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cryotherapy effect, lung adenocarcinoma